When developing our activities, CMEology begins with the identification of practice gaps that result in suboptimal patient outcomes. Gaps may be identified in peer reviewed studies, data from the CDC, WHO, NQF, or AHRQ, epidemiologic and outcomes studies, hospital quality studies, data from previous activities, surveys, interviews, self-reported patient data, and societal trends. Relevance and value are critical aspects in determining if an activity should be initiated.
Value = (Validity x Practice Relevance)/Effort of Implementation
When designing an educational intervention we consider the identified practice gaps and how they relate to principles of adult learning, the learner stage, and evidence for efficacy of the intervention type.
Below is a representative sample of our current activities.
This monograph addresses common challenges and practical solutions faced by providers who care for patients with bipolar depression. What’s unique about this monograph is the interactive format. With this concept, we use current literature as a knowledge base from which to translate clinical data through a question-and-answer format. To view the answer to each question, learners use a “secret decoder” / acetate revealer.
Health Spectrum is a dynamic platform designed for healthcare professionals who want more from their educational experience. Enter our “virtual office,” where 2 interactive patient cases allow you to explore practical considerations for patients with recurrent depression despite adequate trials of antidepressants.
You'll start with Melissa, a 42-year-old woman who is experiencing symptoms of depression after a trial of a selective serotonin reuptake inhibitor (SSRI) followed by Brandon, a 43-year old man who has an inadequate response to two trials of antidepressants. Navigate each patient’s chart, viewing text, videos, and animated graphs. Click on colored/hyperlinked words for extra “pop-up” information in each tab. You'll also hear expert commentary from our faculty, Rakesh Jain, MD, Clinical Professor, Department of Psychiatry, Texas Tech Health Sciences Center School of Medicine.
Clinical management of patients with hemophilia has become increasingly complex due to the introduction of new treatment strategies, the presence of comorbidities, and increased emphasis on outcomes such as quality of life, to balance both the medical and lifestyle consequences of the disease. Patients with severe hemophilia have the greatest need for comprehensive care including primary prophylaxis, overcoming problems relating to inhibitor development, and monitoring for arthropathies. Contemporary strategies include embracing the comprehensive care model, which focuses on the prevention of morbidity and mortality while promoting a high quality of life characterized by a lifestyle that overcomes the limitations of hemophilia. The application of current strategies and recent innovations provides new hope to prevent subclinical bleeding, achieve zero bleeds, and optimize care for each individual patient with hemophilia A. In this enduring activity, expert faculty will provide an update on the state-of-the-art advancements in the management of patients with hemophilia A to decrease the burden of disease. Discussions will include capturing missed opportunities in subclinical bleeding, factor-based prophylaxis, and an update on new developments in the diagnosis and management of hemophilia A.
Hear from Dr. Arlene Chapman, Professor of Medicine at the University of Chicago and one of the leading experts in ADPKD, in this multimedia text article, which features videos with expert commentary and animated slides with narration. A case study approach is used to illustrate the latest advancements in the diagnosis and treatment of this rare disease, as well as prediction of disease progression, clinical manifestations, and management. Two clinical tools will be available for download. The first tool is a questionnaire designed to assist in screening and testing for ADPKD. The second tool is a handout with helpful information for the newly diagnosed patient.
In this activity, experts in multiple sclerosis will discuss current views of the pathophysiology and immunopathogenesis of the condition. The increasing understanding of the immunopathogenesis of MS and the greater availability of disease-modifying therapies (DMTs) have shifted the aims of treatment. Modification of therapies is increasingly common in the context of growing knowledge of MS pathophysiology and DMT mechanisms of action. Education is needed to reformulate treatment strategies on the individual and systems levels.